Regresar

Adalimumab for induction of histological remission in moderately to severely active ulcerative colitis

Abstract:

Background Histological remission represents a target distinct from endoscopic healing in ulcerative colitis (UC) and seems a better predictor of clinical outcomes. Aims The aim of this study was to assess the ability of adalimumab to achieve histological remission in UC patients. Methods Single-center, retrospective, open-label study of patients treated with adalimumab. Eligible patients were anti-TNF naïve adults with moderately to severely active UC. The Mayo score including endoscopy was performed at baseline and weeks 8 and 52. Histological activity was scored using the Geboes Index. The primary endpoint was histological remission, defined as a Geboes grade ≤ 3.0, at week 52. Results We included 34 patients. At week 8, 6 of 34 patients (17.6%) achieved histological …